drugset / Trial / NCT04498741
Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects
Phase 1
Completed
89 enrolled
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates · collab
Non-randomizedSingle-groupOpen-labelBasic science
Summary
A Non-Randomized, Open-Label, Three-Part, Drug-Drug Interaction Study to Evaluate the Effects of tacrolimus, dabigatran, rosuvastatin and midazolam on the Pharmacokinetics and Safety of EDP-938 in Healthy Subjects
Timeline
- Start
- 2020-07-08
- Primary completion
- 2021-05-27
- Completion
- 2021-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dabigatran | Unknown | — | — |
| Subject | Midazolam | Small molecule | — | — |
| Subject | Rosuvastatin | Small molecule | — | — |
| Subject | Tacrolimus | Small molecule | — | — |
| Subject | zelicapavir | Small molecule | — | — |